Bibliographic record
Abstract
Genitourinary MedicalOncologists of Canada (GUMOC) consensus on the management of unresectable locally advanced and metastatic urothelial carcinoma, published in 2019, marked a pivotal moment in the field. 1 It arrived just as we were navigating an unprecedented influx of early-phase trials involving immune checkpoint inhibitors (ICIs) for patients who were refractory or ineligible to platinum.The uro-oncology community was then just transitioning from applauding results at conferences and implementing ICIs in clinics to grappling with the complexities of programmed death-ligand 1 (PD-L1) assays and lack of predictive markers of response.It was evident that we were at the forefront of a significant shift; however, the shadow of the threedecade-long hegemony of platinum doublet persisted in treatment-naive patients, with the same "old" benefits and challenges.Little did we know that changes were just beginning.Fast forward to the 2024 edition of the report in this month's issue of CUAJ, which introduces new classes of therapy against bladder cancers, including novel antibody-drug conjugates (ADC), targeted therapies, and new combination regimens. 2The authors meticulously dissect practice-changing trials and their implementation across first-line treatment, both de novo and post-adjuvant ICI, as well as second-line and beyond.This progress represents much-anticipated breakthroughs for patients and clinicians.Most notably, enfortumab vedotin combined with pembrolizumab (EV + P) has replaced cisplatin-based chemotherapy as the new gold-standard first-line treatment in this
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.004 | 0.003 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.003 | 0.000 |
| Scholarly communication | 0.002 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.001 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".